For the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody
via Whats New Vaccines Blood Biologics RSS Feed https://ift.tt/yVlqLtr
No comments:
Post a Comment